

# 3rd Edelris Symposium on Affinity Selection-Mass Spectrometry in Drug Discovery

## Confirmed Speakers

### Confirmed speakers

#### PL08 - Improved ASMS Affinity Ranking Using Complete Analysis of Target Titration Data



Dr Brett BABIN  
(GENENTECH, South San Francisco, United States)

#### PL01 - Accelerating Throughput of ASMS Screens by Leveraging Multiplexed LC-MS and Automated Data Processing



Dr Gerald BARNEY  
(BRISTOL MYERS SQUIBB, Princeton, United States)

#### PL05 - MALDI MS-based Cell Assays in Pharmaceutical R&D – a Perspective



Prof. Carsten HOPF  
(UNIVERSITY OF MANNHEIM, Mannheim, Germany)

#### PL03 - Deploying Affinity Selection Mass Spectrometry (ASMS) for Rapid and Flexible Hit Confirmation of DNA-Encoded Library (DEL) Screening in Targeted Protein Modulation (TPM)



Dr Daniel MEDINA-CLEGHORN  
(NURIX THERAPEUTICS, San Francisco, United States)

#### PL04 - Affinity Selection Mass Spectrometry: Hit Validation Tool and a Promising High Throughput Screening Platform for Drug Targets



Dr Omprakash NACHAM  
(ABBVIE, North Chicago, United States)

#### PL02 - EDEN in Drug Discovery



Dr Didier ROCHE  
(EDELRIIS, Lyon, France)

#### PL07 - Setting up an AS-MS Screening Method in Pharmaceutical Industry



Mr Kai SINERVO  
(ORION CORPORATION, Espoo, Finland)

#### PL06 - Development of High Throughput MS within AstraZeneca's Discovery Sciences



Dr Jonathan WINGFIELD  
(ASTRAZENECA, Macclesfield, United Kingdom)